Bicyclic oxopyridine and oxopyrimidine derivatives

Details Bicyclic oxopyridine and oxopyrimidine derivatives Bicyclic oxopyridine and oxopyrimidine derivatives

2007-02-13

2007-02-13

McKenzie, Thomas (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S301000, C546S114000, C546S113000, C544S278000, C544S255000

Reexamination Certificate

active

10492466

ABSTRACT:
Compounds of formulae (1a) and (1b) are described: in which the dashed line represents an optional bond; A is a —N═ atom or a —N(Rb)—, —C(Rb)═ or —C(Rb)(RC)— group; Ra, Rband Rcis each independently a hydrogen atom or an optionally substituted C1-6alkyl group; X is an —O— or —S— atom or —NH— group or substituted N atom; each Y is independently a N atom or CH group or substituted C atom; n is zero or the integer 1; Alk1is an optionally substituted aliphatic or heteroaliphatic chain L1is a covalent bond or a linker atom or group; Cy1is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof; The compounds are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritis

REFERENCES:
patent: 0 090 275 (1987-10-01), None
patent: 0 623 598 (1994-11-01), None
patent: 07076586 (1995-03-01), None
patent: 09059276 (1997-04-01), None
patent: WO 99/64400 (1999-12-01), None
patent: WO 01/37837 (2001-05-01), None
patent: WO 01/64679 (2001-09-01), None
Henry et al., “Potent Inhibitors of the Map Kinase p. 38”, CA 130:177125.
Jae Youl Cho et al., “In vitro Inhibitory Efect of Protopanaxadiol Ginsenosides on Tumor Necrosis Factor (TNF)-α Production and its Modulation by known TNF-α Antagonists”, Planta Med, pp. 213-218.
Kui Liu et al., “Sle 1 ab Mediates the Aberrant Activation of STAT3 and Ras-ERK Signaling Pathways in B Lymphocytes”, The Journal of Immunology, pp. 1630-1637.
Valerie Duplan et al., “LF 15-0195 Treatment Protects against Central Nervous System Autoimmunity by Favoring the Development of Foxp3-Expressing Regulatory CD4 T Cells”, The journal of Immunology, pp. 839-847.
Andreas Pascher et al., “Biologics in the Treatment of Transplant Rejection and Ischemia/Reperfusion Injury”, Biodrugs, pp. 211-231.
Tochiro Tatee et al., “Isoxazole derivatives as Centrally Acting Muscle Relaxants. III. Synthesis and Activity of Conformationally Restricted Analogs”, Chemical & Pharmaceutical Buletin, pp. 3676-3690.
Adams, J.L., et al., “p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines,” Progress in Medicinal Chemistry,Elsevier Science, King, F.D., et al. (Eds.), 2001, 38, 1-60.
Allen, M., et al., “Deficiency of the stress kinase p38α results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells,”J. Exp. Med., 2000, 191, 859-869.
Badger, A.M., et al., “Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function,”J. Pharm.&Exp. Ther., 1996, 279, 1453-1461.
Chan, D.T., et al., “New N- and O-arylations with phenylboronic acids and cupric acetate,”Tetrahedron Letts., 1998, 2933-2936.
Cohen, P., “The search for physiological substrates of MAP and SAP kinases in mammalian cells,”Trends Cell Biol., 1997, 7, 353-361.
Dinarello, C.A., “An update on human interleukin-1: from molecular biology to clinical relevance,”J. of Clinical Immunology, 1985, 5(5), 287-297.
Doza, Y.N., et al., “Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues are phosphorylated in chemically stressed KB cells,”FEBS Lett., 1995, 364, 223-228.
Enslen, H., et al., “Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6,”J. of Biol. Chem., 1998, 273(3), 1741-1748.
Glamkowski, E.J., et al., “3-(1-indolinyl)benzylamines: a new class of analgesic agents,”J. Med. Chem., 1985, 28, 66-73.
Griswold, D.E., et al., “Pharmacology of cytokine suppressive anti-inflammatory drug binding protein (CSBP), a novel stress-induced kinase,”Pharmacol. Comm., 1996, 7, 323-329.
Grunberg, K., et al., “Effect of rhinovirus 16 (RV16) cold on airway responsiveness to indirect stimuli in asthmatics,”Am. J. Crit. Care Med., 1997, 155, p. A743 (abstract).
Hale, K.K., et al., “Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages,”Am. J. of Immun., 1999, 162, 4246-4252.
Hunter, T., “Protein kinase classification,”Methods in Enzymology, Academic Press, 1991, 200, 3-37.
Ishii, H., et al., “Fischer indolisation and related compounds. Part 21. Direction on the cyclisation in the Fischer indolisation of ethyl pyruvate 2-)p- orm-substituted phenyl)phenylhydrazones,”J. Chem. Soc. Perkin Trans. 1, 1989, 2407-2414.
Kotlyarov, A., et al., “MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis,”Nature Cell Biol., 1999, 1, 94-97.
Kundu, N.G., et al., “A highly convenient procedure for the synthesis of 5-(2-acylvinyl)uracils, a group of novel 5-substituted uracils,”J. Chem. Soc. Perkin Trans. 1, 1990, 1822-1824.
Lam, P.Y.S., et al., “Copper-catalyzed general C-N and C-O bond cross-coupling with arylboronic acid,”Tetrahedron Letts., 2001, 3415-3418.
Lee, J.C., et al., “Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors,”Annals N.Y. Acad. Sci., 1993, 696, 149-170.
Lee, J.C., et al., “Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002,”Int. J. Immunopharm., 1988, 10(7), 835-843.
Lee, J.C., et al., “A protein kinase involved in the regulation of inflammatory cytokine biosynthesis,”Nature, 1994, 372, 739-746.
Mahadevan, I., et al., “synthesis of pyrrolopyridines (azaindoles),”J. Heterocyclic Chem., 1992, 29, 359-367.
Mann, G., et al., “Palladium-catalyzed C-N9sp2) bond formation:N-arylation of aromatic and unsaturated nitrogen and the reductive elimination chemistry of palladium azolyl and methyleneamido complexes,”J. Am. Chem. Soc., 1998, 120, 827-828.
Mattson, R.J., et al., “Ortho-directed lithiation in π-deficient diazinyl heterocycles,”J. Org. Chem., 1990, 55, 3410-3412.
McDonnell, P.C., et al., “Localization of the human stress responsive MAP kinase-like CSAIDs binding protein (CSBP) gene to chromosome 6p21.3/21.2,”Genomics, 1995, 28, 301-302.
Subauste, M.C., et al., “Infection of a human respiratory epithelial cell line with rhinovirus, Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure,”J. Clin. Invest., 1995, 96, 549-557.
Stabler, S., et al., “Preparation ofN-arylated heterocycles by nucleophilic aromatic substitution,”Synth. Commun., 1994, 24(1), 123-129.
Takekawa, M., et al., “A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK,”Cell, 1998, 95, 521-530.
Turck, A., et al., “Metallation of diazines II. First metallation of pyridazine, metallation of 2,4-dichloropyrimidine,”J. Het. Chem., 1990, 27, 1377-1381.
Turner, R.B., et al., “Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds,”Clin. Infec. Dis., 1998, 26, 840-846.
Zhu, Z., et al., “Rhinovirus stimulation of interleukin-6 in vivo and in vitro, evicence for nuclear factor κB-dependent transcriptional activation,”J. of Clin. Invest., 1996, 97(2), 421-430.

Affiliated with

Also associated with

Rating

Bicyclic oxopyridine and oxopyrimidine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic oxopyridine and oxopyrimidine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic oxopyridine and oxopyrimidine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3831445